The Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma is not an Aggressive Subtype of Papillary Carcinoma

Hiroto Yamashita1, Shiro Noguchi2, Hiroshi Takahashi2, Shin Watanabe2, Shinya Uchino2, Tsukasa Murakami3, Hitoshi Noguchi3, Yui Nishijima3, Tomohiko Nakamura3, Naoyuki Higaki3, Masato Nakamoto3, Yasushi Noguchi4 and Akiko Nakashima4

1Department of Diagnostic Pathology, Noguchi thyroid clinic and hospital foundation, Japan
2Department of Surgery, Noguchi thyroid clinic and hospital foundation, Japan
3Department of Internal Medicine, Noguchi thyroid clinic and hospital foundation, Japan
4Department of Radiology, Noguchi thyroid clinic and hospital foundation, Japan

Corresponding author: Hiroto Yamashita, Department of Diagnostic Pathology, Noguchi thyroid clinic and hospital foundation, Japan, Tel: 81-977-21-2151; Fax: 81-977-21-2155; E-mail: hyp3141@noguchi-med.or.jp

Rec date: August 13, 2014; Acc date: September 22, 2013; Pub date: September 24, 2014

Abstract

Background: The diffuse sclerosing variant of papillary thyroid carcinoma (DSV) is a rare subtype of papillary thyroid carcinoma (PTC), and the prognosis of patients with this variant is not yet fully understood. The aim of this study was to determine whether DSV is a poorer prognostic factor than non-DSV.

Methods: We reviewed the histologic slides of 12,664 primary PTC cases and divided them into DSV and non-DSV groups. Based on the results of the follow-up study and the age distribution of patients, we selected the data from 810 female patients and compared outcomes between patients with DSV and patients with non-DSV.

Results: Of all initial patients, 43 had DSV. Of these, 4 patients were deceased, and 39 were alive with a mean survival of 11.1 ± 9.7 years (mean ± SD) after surgery; the deceased patients were all female patients with papillary non-microcarcinoma (PNMC, >10 mm diameter). A substudy of female PNMC patients by age showed that a cutoff at age 33 years was optimal for analyzing the DSV and non-DSV groups. Of 810 female patients younger than 33 years with PNMC, 25 had DSV and 785 had non-DSV. Of the patients with non-DSV, 23 patients died, including 5 deaths from PTC. The overall mortality and disease-specific mortality rates of the selected patients were not statistically significant between the DSV and non-DSV groups (2/25 vs. 23/785, p=0.18 and 1/24 vs. 5/767, p=0.17, respectively).

Conclusion: DSV is not an aggressive subtype of PTC and patients with DSV do not require more aggressive therapy than patients with non-DSV of the same stage.

Keywords: Papillary thyroid carcinoma; Sclerosing variant

Introduction

In 1953, Crile and Fisher were the first to report papillary thyroid carcinoma (PTC) diffusely intermingled with chronic thyroiditis [1], which was later named diffuse sclerosing variant of papillary thyroid carcinoma (DSV) [2]. In 1989, Carcangiu and Bianchi characterized the various histological findings of DSV, which include diffuse involvement of one or both lobes, numerous micropapillary formations located within cleft-like spaces consistent with lymph vessels, extensive squamous metaplasia, large number of psammoma bodies, marked lymphocytic infiltration, and prominent fibrosis; of these, intrathyroidal lymphatic permeation was thought to be the most important feature of DSV [3].

The clinicopathologic characteristics of DSV are now well established [4], but the prognosis of patients with DSV remains uncertain [4,5]. For this reason, this study was undertaken to determine whether DSV is a poor prognostic subtype of PTC.

Patients and Methods

Between January 1971 and December 2013, 12,662 consecutive patients with primary PTC underwent initial surgery at Noguchi Thyroid Clinic and Hospital foundation. Except for patients with incidental PTC (PTC first found at the postoperative pathological examination), they were treated with conventional treatment for PTC, and postoperative radioiodine ablation therapy was not performed. Subtotal thyroidectomy with a modified radical neck dissection is our standard procedure for papillary thyroid carcinoma [6].

We reviewed the histologic specimens of these patients and divided the cases into DSV and non-DSV groups according to the 2004 World Health Organization Classification of the Tumors [4]. Papillary thyroid carcinoma with lymphatic permeation was diagnosed as DSV (Figure 1). The sex ratio, age distribution, and ratio of patients with papillary microcarcinoma (PMC, ≤ 10 mm diameter) to patients with papillary non-microcarcinoma (PNMC) were compared between the 2 groups.
and information about the final hospital stay was obtained from the death certificate and the Japanese family registry, respectively. Of the initial group of 12,662 patients with PTC, 43 patients, including 3 male patients, had DSV. The incidence of DSV among patients with PTC was 0.3% (43/12,662), and excluding patients with PMC, the incidence was 0.6% (38/6,603).

Of the 43 patients with DSV, macroscopic figures of the cut surface were available for 25 cases. No dominant nodule, a dominant nodule with a clear margin were found in 3, 8, and 14 cases, respectively

Table 1 summarizes the age distribution, the female to male ratio, and the PMC to PNMC ratio of patients with DSV and patients with non-DSV. Patients with DSV were much younger than those with non-DSV. Female patients were predominant in both groups, and the difference in sex ratio was not statistically significant. The ratio of PMC to PNMC was lower in the DSV group.

Table 1: Comparison of patients with DSV and non-DSV

<table>
<thead>
<tr>
<th></th>
<th>DSV</th>
<th>Non-DSV</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y, mean ± SD)</td>
<td>33 ± 15</td>
<td>51 ± 14</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Female/male ratio</td>
<td>40/3</td>
<td>10972/1847</td>
<td>0.3604</td>
</tr>
<tr>
<td>PMC/PNMC* ratio</td>
<td>5/38</td>
<td>6054/6565</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

*PMC, papillary microcarcinoma; PNMC, papillary non-microcarcinoma; DSV, diffuse sclerosing variant of papillary thyroid carcinoma

Table 2 shows the age at the initial surgery, the duration of survival after surgery, and the causes of death of these 4 patients. Two patients died within 5 years of the initial surgery, and other 2 died more than 30 years after the initial surgery. The cause of death was related to thyroid carcinoma in 1 patient, not related to thyroid carcinoma in 2 patients, and difficult to determine in 1 patient (the third patient in Table 2). The first patient in Table 2 had advanced cancer (stage 4) at the initial presentation. She underwent palliative surgery with tracheostomy and died 2 months after surgery owing to invasive growth of PTC. The second and fourth patients showed neither nodal recurrence nor distant metastasis and died of other causes. The third patient developed regional nodal recurrence 8 years after surgery and pulmonary metastasis 12 years after surgery. This patient’s nodal recurrence was successfully surgically removed, and the pulmonary metastasis was treated several times with radioiodine. The metastatic pulmonary nodules diminished in size but did not disappear completely and remained without re-growth. This patient’s serum thyroglobulin (TG) levels were high, with a final serum TG level of 5100 mg/ml at the age of 32. She died at the age of 46. According to a physician at a referring hospital, her cause of death was multiple organ failure initiated by interstitial pneumonitis and was probably not related to pulmonary metastasis of PTC. For our analysis, however, we made the assumption that she had died of DSV.

Table 2: Fatalities among patients with DSV, listed in order of survival.

<table>
<thead>
<tr>
<th>Age at surgery (y)</th>
<th>Survival duration (y)</th>
<th>Cause of death</th>
</tr>
</thead>
<tbody>
<tr>
<td>66</td>
<td>0.2</td>
<td>DSV</td>
</tr>
<tr>
<td>31</td>
<td>4.8</td>
<td>Accident</td>
</tr>
<tr>
<td>16</td>
<td>31.0</td>
<td>Multiple organ failure</td>
</tr>
<tr>
<td>44</td>
<td>33.2</td>
<td>Dilated cardiomyopathy</td>
</tr>
</tbody>
</table>

Thyroid Disorders Ther
ISSN:2167-7948 JTDT, an open access
As shown in Table 1, patients with DSV were much younger than patients with non-DSV, and age is a major prognostic factor of PTC. For this reason, a substudy of female patients with PNMC was performed according to patient age. As shown in Figure 2, an age cutoff of 33 years was optimal for analyzing the DSV and non-DSV groups.

A total of 810 female patients under the age of 33 with PNMC were selected for the substudy analysis. Of these patients, 25 had DSV and 785 had non-DSV.

Figure 3 shows the disease-free survival curves of the 810 patients. Disease-free survival rate of DSV was significantly worse than that of non-DSV by Wilcoxon test (P value, 0.001) but not significantly worse by log-rank test (P value, 0.17).

Discussion

The overall incidence of DSV in PTC has been reported to range from 0.1% [7] to 6% [8]. Similarly, Fukushima et al. found that after excluding cases of PMC, the incidence of DSV in PTC was 0.7% [9], which is consistent with our result of 0.6%.

The present study confirmed the predominance of DSV among young women [3,10]. However, female predominance is a characteristic finding of PTC in general.

Although DSV is considered a non-tumor forming carcinoma [4], Carcangiu et al. reported the presence of a tumor-forming type of DSV, in which the tumor-forming type was more predominant than the non-tumor-forming type. They suggested that DSV might begin as a tumor-forming cancer type and change into a non-tumor forming cancer type [3]. In the present study, the macroscopic finding of nodules with clear margins, nodules with blurred margins, and cancers without nodules seems to support this suggestion.

On the disease-free survival period, our follow-up study showed little bit complicated results. Although several interpretations may be possible, we considered that these results were related to wider spread cancer cells in DSV than in non-DSV.

On the mortality, our follow-up study showed that DSV was not a worse prognostic factor than non-DSV. Falvo et al. found that the mortality rate of patients with DSV was higher than the mortality rate of patients with conventional PTC. However, in their study, there was a marked imbalance between the cancer stages of the two groups. Patients with DSV outnumbered patients with conventional PTC in advanced cancer stages, and vice versa in the pT1 stage [11]. In other reports, including the present one, patients who had died of DSV had incomplete excision of the cancer initially and/or had distant metastasis at the initial presentation [9,12]. These reports suggest that the fatality of patients with DSV is not related to the DSV itself but rather to the advanced tumor stage [13] at the initial presentation.

Using the hazard function on data from the SEER Program, Vollmer reported that 56% of fatalities of patients with thyroid carcinoma occur within two years after surgery (rapidly evolving tumor group), and that approximately 80% of tumor-related fatalities occur by 10 years. In his report, PTCs with higher initial stages belonged to the rapidly evolving tumor group [14]. The study by Vollmer also supports the idea that DSV is not an aggressive subtype of PTC. In the present study, the one patient who died of DSV 2 months after surgery had a higher initial cancer stage (stage 4). The other 2 deceased patients who had received radical surgery (this excludes the patient who died in an accident) survived more than 30
years after the surgery. In conclusion, DSV is not an aggressive subtype of PTC and therefore does not require more aggressive therapy than PTC of the same stage.

References